Mercodia’s Lispro Northern Lights (NL)-ELISA provides a chemiluminescent method for the quantitative determination of insulin lispro.
Lispro is a rapid-acting insulin analogue that was first introduced in 1996 to treat people with diabetes. Mercodia’s Lispro NL-ELISA, a novel pharmacokinetics (PK) assay, is both sensitive and specific for determination of insulin lispro. With pre-diluted calibrators in serum matrix at six levels, as evidenced by the robust assay performance characteristics, this method is suitable for multiple phases of drug development and meets the requirements of EMA and FDA validation.
The Lispro NL-ELISA Kit enables a broad measuring range, is fully validated for use with human and porcine samples, and requires a low sample volume of 10 μL. The ELISA kit has no cross-reactivity to endogenous insulin or other insulin analogues and has no interference from insulin auto-antibodies. Additionally, the kit gives results in just 2 h 15 min.
Phone: 02 9698 2022
Lonza 4D-Nucleofector LV Unit PRO electroporation unit
Lonza's 4D-Nucleofector LV Unit PRO is a next-generation, large-scale electroporation unit...
Cytek 25-Color Immunoprofiling Assay, cFluor Reagent Kit (18C)
The Cytek 25-Color Immunoprofiling Assay has been designed and optimised to provide a turnkey...
Bio-Rad Laboratories QX Continuum and QX700 series ddPCR platforms
The latest platforms complement Bio-Rad's existing QX ddPCR portfolio and offer users...